Novo Nordisk A/S $NVO Shares Purchased by CW Advisors LLC

Key Points

• CW Advisors LLC increased its stake in Novo Nordisk A/S by 259.1% during the first quarter, holding 64,914 shares valued at approximately $4.63 million.
• Analysts have mixed ratings for Novo Nordisk, with three "Buy" ratings, eleven "Hold" ratings, and two "Sell" ratings, resulting in a consensus price target of $81.00.
• Novo Nordisk recently announced a semi-annual dividend of $0.4119 per share, with a payout ratio of 22.53%, despite cutting its dividend in recent times.

CW Advisors LLC boosted its position in Novo Nordisk A/S (NYSE:NVO - Free Report) by 259.1% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 64,914 shares of the company's stock after buying an additional 46,835 shares during the period. CW Advisors LLC's holdings in Novo Nordisk A/S were worth $4,633,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in the stock. Bank of America Corp DE boosted its position in shares of Novo Nordisk A/S by 8.1% during the 4th quarter. Bank of America Corp DE now owns 15,492,384 shares of the company's stock worth $1,332,655,000 after purchasing an additional 1,165,955 shares in the last quarter. Folketrygdfondet raised its stake in shares of Novo Nordisk A/S by 6.9% during the 1st quarter. Folketrygdfondet now owns 9,521,912 shares of the company's stock worth $661,202,000 after buying an additional 617,974 shares during the last quarter. Nuveen Asset Management LLC raised its stake in shares of Novo Nordisk A/S by 73.2% during the 4th quarter. Nuveen Asset Management LLC now owns 6,244,931 shares of the company's stock worth $537,189,000 after buying an additional 2,639,693 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Novo Nordisk A/S by 11.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 5,692,554 shares of the company's stock worth $395,291,000 after buying an additional 576,900 shares during the last quarter. Finally, Sustainable Growth Advisers LP raised its stake in shares of Novo Nordisk A/S by 3.8% during the 1st quarter. Sustainable Growth Advisers LP now owns 5,543,246 shares of the company's stock worth $384,923,000 after buying an additional 202,443 shares during the last quarter. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Novo Nordisk A/S Price Performance

NVO stock traded down $0.63 during trading on Monday, hitting $56.35. The stock had a trading volume of 16,131,337 shares, compared to its average volume of 29,651,820. The company's 50 day moving average price is $62.16 and its two-hundred day moving average price is $69.00. Novo Nordisk A/S has a 1-year low of $45.05 and a 1-year high of $139.74. The stock has a market cap of $251.60 billion, a price-to-earnings ratio of 15.48, a price-to-earnings-growth ratio of 1.98 and a beta of 0.63. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.56 and a current ratio of 0.78.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported $0.97 EPS for the quarter, beating analysts' consensus estimates of $0.93 by $0.04. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. The company had revenue of $11.69 billion during the quarter, compared to the consensus estimate of $77.51 billion. On average, sell-side analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The business also recently disclosed a semi-annual dividend, which will be paid on Tuesday, August 26th. Stockholders of record on Monday, August 18th will be paid a dividend of $0.4119 per share. The ex-dividend date of this dividend is Monday, August 18th. This represents a dividend yield of 240.0%. Novo Nordisk A/S's dividend payout ratio is currently 22.53%.

Analyst Upgrades and Downgrades

NVO has been the subject of several research reports. HSBC downgraded Novo Nordisk A/S from a "buy" rating to a "hold" rating and set a $57.00 price target for the company. in a research note on Thursday, July 31st. UBS Group downgraded Novo Nordisk A/S from a "buy" rating to a "neutral" rating in a research note on Tuesday, August 5th. BNP Paribas Exane raised Novo Nordisk A/S from an "underperform" rating to a "neutral" rating and set a $54.00 price target for the company in a research note on Wednesday, August 13th. BNP Paribas raised Novo Nordisk A/S from an "underperform" rating to a "neutral" rating in a research note on Wednesday, August 13th. Finally, Wall Street Zen downgraded Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research note on Saturday, August 2nd. Three analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat.com, Novo Nordisk A/S presently has an average rating of "Hold" and an average price target of $81.00.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.